Prevention of venous thromboembolism.
Geerts
W H
WH
Thromboembolism Program, Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada.
Heit
J A
JA
Clagett
G P
GP
Pineo
G F
GF
Colwell
C W
CW
Anderson
F A
FA
Wheeler
H B
HB
D002056:Burns / Q000150:complications; D003422:Critical Care; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009369:Neoplasms / Q000150:complications; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000517:prevention & control*; D018570:Risk Assessment; D013119:Spinal Cord Injuries / Q000150:complications; D020521:Stroke / Q000188:drug therapy; D020246:Venous Thrombosis / Q000453:epidemiology / Q000517:prevention & control*; D014947:Wounds and Injuries / Q000150:complications
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin